It’s World Osteoporosis Day today and the Veri-te™ resveratrol team would like to help raise awareness of this valuable day and this condition that affects so many people.
- Osteoporosis affects 75 million people in Europe, the US and Japan.
- It is estimated to affect 200 million women.
- Globally there are >8.9 million fractures a year.
- 1 in 3 women 50+ experience osteoporotic fractures in their lifetime as will 1 in 5 men over 50 years.
- Just a 10% loss of bone mass doubles the risk of fracture in the vertebrae and is associated with a 2.5 risk in hip fractures.
These are startling statistics.
The International Osteoporosis Foundation recommend a combination of therapies for treatment and prevention. Among these therapies is nutritional supplementation to support healthy bones.
Veri-te™ Resveratrol and Bone Health
If you are thinking of developing a new bone health supplement to meet this market demand you may be interested in the science that is available.
Two published studies using Veri-te™ resveratrol have shown:
- A significant increase in bone specific alkaline phosphatse (BAP)1,2
- A dose-dependent increase in spinal bone mineral density2
- That resveratrol supplementation may affect bone primarily by stimulating formation or mineralisation2
These results suggest that resveratrol promotes the formation of new bone-forming cells. Therefore, resveratrol supports bone health in a way that complements, rather than duplicates, the actions of Vitamin D and Calcium3 making it a vital addition to bone health products.
At Newcastle University in Australia Professor Peter Howe is conducting an important study4 at looking at the effects of 2 x 75mg/day Veri-te™ resveratrol supplementation on parameters in bone and cognitive health in 170 post-menopausal women. This study started in June this year and will last 24 months.
To find out more click to download our Veri-te™ Resveratrol Bone Health brochure.
Interested in developing a new Bone Health product with Veri-te™? We’d love to hear from you:
Gene Adamski (US sales)
Clare Panchoo (EMEA)
Luc Gruner (Japan)
Angela Tsetsis (Global sales & ROW)
- Poulsen MM, Ornstrup MJ, Harsløf T, et al. Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men. J Funct Foods 2014;6:305–310.
- Ornstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2014;99(12):4720–4729.
- Ornstrup MJ, Harsløf T, Sørensen L, Stenkjær L, Langdahl BL, Pedersen SB. Resveratrol Increases Osteoblast Differentiation In Vitro Independently of Inflammation. Calcif Tissue Int. 2016 Aug;99(2):155-63.
- Resveratrol for Healthy Ageing in Women. Universal Trial Number (UTN): U1111-1182-8860. https://www.anzctr.org.au/Trial/ Registration/Trial Review.aspx?id=370696